A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT03823300
- Phase
- PHASE3
- Status
- Completed
Conditions
- Wet Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Faricimab — DRUGFaricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
- Aflibercept — DRUGAflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
- Sham Procedure — PROCEDUREThe sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
Study Details
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
Key Dates
- Start date
- Mar 11, 2019
- Status verified
- Jul 2025
- Primary completion
- Oct 5, 2020
- Completion
- Jan 7, 2022
Study Design
- Enrollment
- 658 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Faricimab
- Active Comparator: Arm B: Aflibercept
Primary Outcome Measure
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 [ Time Frame: From Baseline through Week 48 ]
Locations (41)
Find similar trials in Phoenix, AZ
By research site
Related Studies
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)PHASE2/PHASE3 · Recruiting · EyeBiotech Ltd. · Springdale, Arkansas
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)PHASE2/PHASE3 · Recruiting · EyeBiotech Ltd. · Mountain View, California